Cellular Responses and Tissue Depots for Nanoformulated Antiretroviral Therapy.

Long-acting nanoformulated antiretroviral therapy (nanoART) induces a range of innate immune migratory, phagocytic and secretory cell functions that perpetuate drug depots. While recycling endosomes serve as the macrophage subcellular depots, little is known of the dynamics of nanoART-cell interacti...

Full description

Bibliographic Details
Main Authors: Andrea L Martinez-Skinner, Mariluz A Araínga, Pavan Puligujja, Diana L Palandri, Hannah M Baldridge, Benson J Edagwa, JoEllyn M McMillan, R Lee Mosley, Howard E Gendelman
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2015-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC4696780?pdf=render
id doaj-4edb165520984c83af62b4a2df1b1354
record_format Article
spelling doaj-4edb165520984c83af62b4a2df1b13542020-11-24T22:04:46ZengPublic Library of Science (PLoS)PLoS ONE1932-62032015-01-011012e014596610.1371/journal.pone.0145966Cellular Responses and Tissue Depots for Nanoformulated Antiretroviral Therapy.Andrea L Martinez-SkinnerMariluz A AraíngaPavan PuligujjaDiana L PalandriHannah M BaldridgeBenson J EdagwaJoEllyn M McMillanR Lee MosleyHoward E GendelmanLong-acting nanoformulated antiretroviral therapy (nanoART) induces a range of innate immune migratory, phagocytic and secretory cell functions that perpetuate drug depots. While recycling endosomes serve as the macrophage subcellular depots, little is known of the dynamics of nanoART-cell interactions. To this end, we assessed temporal leukocyte responses, drug uptake and distribution following both intraperitoneal and intramuscular injection of nanoformulated atazanavir (nanoATV). Local inflammatory responses heralded drug distribution to peritoneal cell populations, regional lymph nodes, spleen and liver. This proceeded for three days in male Balb/c mice. NanoATV-induced changes in myeloid populations were assessed by fluorescence-activated cell sorting (FACS) with CD45, CD3, CD11b, F4/80, and GR-1 antibodies. The localization of nanoATV within leukocyte cell subsets was determined by confocal microscopy. Combined FACS and ultra-performance liquid chromatography tandem mass-spectrometry assays determined nanoATV carriages by cell-based vehicles. A robust granulocyte, but not peritoneal macrophage nanoATV response paralleled zymosan A treatment. ATV levels were highest at sites of injection in peritoneal or muscle macrophages, dependent on the injection site. The spleen and liver served as nanoATV tissue depots while drug levels in lymph nodes were higher than those recorded in plasma. Dual polymer and cell labeling demonstrated a nearly exclusive drug reservoir in macrophages within the liver and spleen. Overall, nanoART induces innate immune responses coincident with rapid tissue macrophage distribution. Taken together, these works provide avenues for therapeutic development designed towards chemical eradication of human immunodeficiency viral infection.http://europepmc.org/articles/PMC4696780?pdf=render
collection DOAJ
language English
format Article
sources DOAJ
author Andrea L Martinez-Skinner
Mariluz A Araínga
Pavan Puligujja
Diana L Palandri
Hannah M Baldridge
Benson J Edagwa
JoEllyn M McMillan
R Lee Mosley
Howard E Gendelman
spellingShingle Andrea L Martinez-Skinner
Mariluz A Araínga
Pavan Puligujja
Diana L Palandri
Hannah M Baldridge
Benson J Edagwa
JoEllyn M McMillan
R Lee Mosley
Howard E Gendelman
Cellular Responses and Tissue Depots for Nanoformulated Antiretroviral Therapy.
PLoS ONE
author_facet Andrea L Martinez-Skinner
Mariluz A Araínga
Pavan Puligujja
Diana L Palandri
Hannah M Baldridge
Benson J Edagwa
JoEllyn M McMillan
R Lee Mosley
Howard E Gendelman
author_sort Andrea L Martinez-Skinner
title Cellular Responses and Tissue Depots for Nanoformulated Antiretroviral Therapy.
title_short Cellular Responses and Tissue Depots for Nanoformulated Antiretroviral Therapy.
title_full Cellular Responses and Tissue Depots for Nanoformulated Antiretroviral Therapy.
title_fullStr Cellular Responses and Tissue Depots for Nanoformulated Antiretroviral Therapy.
title_full_unstemmed Cellular Responses and Tissue Depots for Nanoformulated Antiretroviral Therapy.
title_sort cellular responses and tissue depots for nanoformulated antiretroviral therapy.
publisher Public Library of Science (PLoS)
series PLoS ONE
issn 1932-6203
publishDate 2015-01-01
description Long-acting nanoformulated antiretroviral therapy (nanoART) induces a range of innate immune migratory, phagocytic and secretory cell functions that perpetuate drug depots. While recycling endosomes serve as the macrophage subcellular depots, little is known of the dynamics of nanoART-cell interactions. To this end, we assessed temporal leukocyte responses, drug uptake and distribution following both intraperitoneal and intramuscular injection of nanoformulated atazanavir (nanoATV). Local inflammatory responses heralded drug distribution to peritoneal cell populations, regional lymph nodes, spleen and liver. This proceeded for three days in male Balb/c mice. NanoATV-induced changes in myeloid populations were assessed by fluorescence-activated cell sorting (FACS) with CD45, CD3, CD11b, F4/80, and GR-1 antibodies. The localization of nanoATV within leukocyte cell subsets was determined by confocal microscopy. Combined FACS and ultra-performance liquid chromatography tandem mass-spectrometry assays determined nanoATV carriages by cell-based vehicles. A robust granulocyte, but not peritoneal macrophage nanoATV response paralleled zymosan A treatment. ATV levels were highest at sites of injection in peritoneal or muscle macrophages, dependent on the injection site. The spleen and liver served as nanoATV tissue depots while drug levels in lymph nodes were higher than those recorded in plasma. Dual polymer and cell labeling demonstrated a nearly exclusive drug reservoir in macrophages within the liver and spleen. Overall, nanoART induces innate immune responses coincident with rapid tissue macrophage distribution. Taken together, these works provide avenues for therapeutic development designed towards chemical eradication of human immunodeficiency viral infection.
url http://europepmc.org/articles/PMC4696780?pdf=render
work_keys_str_mv AT andrealmartinezskinner cellularresponsesandtissuedepotsfornanoformulatedantiretroviraltherapy
AT mariluzaarainga cellularresponsesandtissuedepotsfornanoformulatedantiretroviraltherapy
AT pavanpuligujja cellularresponsesandtissuedepotsfornanoformulatedantiretroviraltherapy
AT dianalpalandri cellularresponsesandtissuedepotsfornanoformulatedantiretroviraltherapy
AT hannahmbaldridge cellularresponsesandtissuedepotsfornanoformulatedantiretroviraltherapy
AT bensonjedagwa cellularresponsesandtissuedepotsfornanoformulatedantiretroviraltherapy
AT joellynmmcmillan cellularresponsesandtissuedepotsfornanoformulatedantiretroviraltherapy
AT rleemosley cellularresponsesandtissuedepotsfornanoformulatedantiretroviraltherapy
AT howardegendelman cellularresponsesandtissuedepotsfornanoformulatedantiretroviraltherapy
_version_ 1725828920248369152